Featured Story BioCentury & Getty ImagesNavigating IP strategies in the world of digital therapeutics

For digital therapeutics, which straddle life sciences and tech, IP may be less important to creating value than the data they generate. As biopharma companies move into the world of digital ...

Featured Story BioCentury & Getty ImagesStephen Hahn’s road to White Oak

The path to Stephen Hahn’s confirmation as FDA commissioner is enveloped in clouds of flavored vapor, littered with piles of Impossible Burgers, and passes tanks filled with precocious fish. The Trump ...

Product Development BioCentury & Getty ImagesMajor multinationals open, close, open R&D centers in China

After pulling back to reconsider their strategies, several pharmas are once again plunging into China’s life sciences innovation ecosystem, this time leaning more heavily on creation of innovation ...

Product Development BioCentury & Getty ImagesHua Phase III diabetes data make good on glucokinase but disappoint investors

Hua’s announcement that glucokinase activator dorzagliatin met its endpoints in a Phase III diabetes study marks a watershed moment for a target whose disease-modifying potential was long stymied by ...

Emerging Company Profile Mycovia tackling chronic infections with antifungal pipeline

Mycovia plans to bring a new generation of antifungals against CYP51 to market for difficult-to-treat indications, starting with chronic vaginal and nail infections. The company's lead product VT-1161 ...

Finance BioCentury & Getty ImagesConjugate company Avidity preps for first dystrophy study with $100M series C

Avidity’s $100 million series C round will allow it to evaluate clinical proof of concept for the first antibody-oligonucleotide conjugate from its platform. The company believes it can also fund ...

Finance Shanghai’s STAR rises as a destination for biotech IPOs

An analysis of recent and expected IPOs of Chinese biotechs suggests Shanghai’s STAR market could quickly catch up to, or even surpass, HKEX in the number of biotechs completing IPOs on the exchange. ...

BioCentury ISSN 1097-7201